127 related articles for article (PubMed ID: 18559590)
1. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer.
Lin SH; Lee YC; Choueiri MB; Wen S; Mathew P; Ye X; Do KA; Navone NM; Kim J; Tu SM; Yu-Lee LY; Logothetis CJ
Clin Cancer Res; 2008 Jun; 14(12):3729-36. PubMed ID: 18559590
[TBL] [Abstract][Full Text] [Related]
2. A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells.
Chen N; Ye XC; Chu K; Navone NM; Sage EH; Yu-Lee LY; Logothetis CJ; Lin SH
Cancer Res; 2007 Jul; 67(14):6544-8. PubMed ID: 17638862
[TBL] [Abstract][Full Text] [Related]
3. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation.
Lin SH; Cheng CJ; Lee YC; Ye X; Tsai WW; Kim J; Pasqualini R; Arap W; Navone NM; Tu SM; Hu M; Yu-Lee LY; Logothetis CJ
Oncogene; 2008 Sep; 27(39):5195-203. PubMed ID: 18490922
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of putative cancer stem cell markers in the bone marrow of prostate cancer patients is associated with bone metastasis progression.
Ricci E; Mattei E; Dumontet C; Eaton CL; Hamdy F; van der Pluije G; Cecchini M; Thalmann G; Clezardin P; Colombel M
Prostate; 2013 Dec; 73(16):1738-46. PubMed ID: 24115186
[TBL] [Abstract][Full Text] [Related]
5. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.
Lee H; Akita RW; Sliwkowski MX; Maihle NJ
Cancer Res; 2001 Jun; 61(11):4467-73. PubMed ID: 11389077
[TBL] [Abstract][Full Text] [Related]
6. The single N-glycan deletion mutant of soluble ErbB3 protein attenuates heregulin β1-induced tumor progression by blocking of the HIF-1 and Nrf2 pathway.
Takamiya R; Takahashi M; Uehara Y; Ariki S; Hashimoto J; Hasegawa Y; Kuroki Y
Biochem Biophys Res Commun; 2014 Nov; 454(3):364-8. PubMed ID: 25451255
[TBL] [Abstract][Full Text] [Related]
7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
8. New developments in metastatic prostate cancer therapy.
Manickavasagar T; Gilson C; Chowdhury S; Kirby R
Practitioner; 2015 Apr; 259(1781):21-4, 2-3. PubMed ID: 26529826
[TBL] [Abstract][Full Text] [Related]
9. Effect of androgen blockade on HER-2 and matrix metalloproteinase-2 expression on bone marrow micrometastasis and stromal cells in men with prostate cancer.
Murray NP; Reyes E; Badinez L; Orellana N; Fuentealba C; Olivares R; Porcell J; Dueñas R
ScientificWorldJournal; 2013; 2013():281291. PubMed ID: 23766685
[TBL] [Abstract][Full Text] [Related]
10. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
Domingo-Domenech J; Oliva C; Rovira A; Codony-Servat J; Bosch M; Filella X; Montagut C; Tapia M; Campás C; Dang L; Rolfe M; Ross JS; Gascon P; Albanell J; Mellado B
Clin Cancer Res; 2006 Sep; 12(18):5578-86. PubMed ID: 17000695
[TBL] [Abstract][Full Text] [Related]
11.
Lengana T; Lawal IO; Boshomane TG; Popoola GO; Mokoala KMG; Moshokoa E; Maes A; Mokgoro NP; Van de Wiele C; Vorster M; Sathekge MM
Clin Genitourin Cancer; 2018 Oct; 16(5):392-401. PubMed ID: 30120038
[TBL] [Abstract][Full Text] [Related]
12. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
Meulenbeld HJ; van Werkhoven ED; Coenen JL; Creemers GJ; Loosveld OJ; de Jong PC; Ten Tije AJ; Fosså SD; Polee M; Gerritsen W; Dalesio O; de Wit R
Eur J Cancer; 2012 Nov; 48(16):2993-3000. PubMed ID: 22677260
[TBL] [Abstract][Full Text] [Related]
13. Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate Cancer.
Parker SJ; Pond GR; Agarwal N; Alex A; Heilbrun ME; Sonpavde G
Clin Genitourin Cancer; 2017 Feb; 15(1):53-59. PubMed ID: 27338517
[TBL] [Abstract][Full Text] [Related]
14. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis.
Miller RE; Roudier M; Jones J; Armstrong A; Canon J; Dougall WC
Mol Cancer Ther; 2008 Jul; 7(7):2160-9. PubMed ID: 18606716
[TBL] [Abstract][Full Text] [Related]
15. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma.
Hotte SJ; Winquist EW; Stitt L; Wilson SM; Chambers AF
Cancer; 2002 Aug; 95(3):506-12. PubMed ID: 12209742
[TBL] [Abstract][Full Text] [Related]
16. Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone.
Wu SL; Jones E; Gulley JL; Arlen PM; Chen CC; Figg WD; Dahut WL
BJU Int; 2007 Mar; 99(3):525-8. PubMed ID: 17155971
[TBL] [Abstract][Full Text] [Related]
17. Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells.
Cheng CJ; Ye XC; Vakar-Lopez F; Kim J; Tu SM; Chen DT; Navone NM; Yu-Lee LY; Lin SH; Hu MC
Mol Cancer Res; 2007 Jul; 5(7):675-84. PubMed ID: 17634423
[TBL] [Abstract][Full Text] [Related]
18. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
[TBL] [Abstract][Full Text] [Related]
19. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.
Gravis G; Boher JM; Chen YH; Liu G; Fizazi K; Carducci MA; Oudard S; Joly F; Jarrard DM; Soulie M; Eisenberger MJ; Habibian M; Dreicer R; Garcia JA; Hussain MHM; Kohli M; Vogelzang NJ; Picus J; DiPaola R; Sweeney C
Eur Urol; 2018 Jun; 73(6):847-855. PubMed ID: 29475737
[TBL] [Abstract][Full Text] [Related]
20. Secreted ERBB3 isoforms are serum markers for early hepatoma in patients with chronic hepatitis and cirrhosis.
Hsieh SY; He JR; Yu MC; Lee WC; Chen TC; Lo SJ; Bera R; Sung CM; Chiu CT
J Proteome Res; 2011 Oct; 10(10):4715-24. PubMed ID: 21877752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]